ALSO NOTED: Pro-compulsory license official reassigned in Thailand; Galderma to nab CollaGenex for $420M

> Thailand's FDA chief was transferred to an "inactive post" in a move observers consider linked to the government's rethinking of previous officials' policy of quashing cancer-drug patents. Report

> Dermatology drugs specialist Galderma Pharma said it has agreed to buy CollaGenex Pharmaceuticals for $16.60 per share cash, or $420 million. Report

> Barr Pharmaceuticals reached a $6 million settlement with Iowa and 33 other states that sued the company for agreeing not to launch a generic version of the Warner Chilcott contraceptive Ovcon. Report

> The U.K.'s drug advisory panel says children as young as 12 should get nicotine patches if they have a serious smoking problem. Report

> NPS Pharmaceuticals said its president and CEO Tony Coles would step down to become president and CEO of Onyx Pharmaceuticals; he will be succeeded at NPS by EVP and COO Francois Nader. Report

> More bad news on the big drought of new drug approvals. Not only are approvals at a 25-year low while non-approvable letters and black box warnings are on the rise. Now "refuse-to-file" letters are also spiking. Report

And Finally... One in 20 tuberculosis cases worldwide is now resistant to two or more drugs, and an extensively resistant form is active in 45 countries. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.